150 related articles for article (PubMed ID: 7535774)
21. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch C; Weiss FU; Niederfellner G; Jallal B; Issing W; Ullrich A
EMBO J; 1995 Sep; 14(17):4267-75. PubMed ID: 7556068
[TBL] [Abstract][Full Text] [Related]
22. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
[TBL] [Abstract][Full Text] [Related]
23. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
24. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Barth S; Matthey B; Huhn M; Diehl V; Engert A
Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
[TBL] [Abstract][Full Text] [Related]
25. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
[TBL] [Abstract][Full Text] [Related]
26. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
27. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
[TBL] [Abstract][Full Text] [Related]
28. Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells.
Batra JK; FitzGerald D; Gately M; Chaudhary VK; Pastan I
J Biol Chem; 1990 Sep; 265(25):15198-202. PubMed ID: 2118522
[TBL] [Abstract][Full Text] [Related]
29. Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin.
Gawlak SL; Pastan I; Siegall CB
Bioconjug Chem; 1993; 4(6):483-9. PubMed ID: 7508267
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells.
Kunwar S; Pai LH; Pastan I
J Neurosurg; 1993 Oct; 79(4):569-76. PubMed ID: 7692018
[TBL] [Abstract][Full Text] [Related]
31. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
[TBL] [Abstract][Full Text] [Related]
32. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines.
Klimka A; Barth S; Drillich S; Wels W; van Snick J; Renauld JC; Tesch H; Bohlen H; Diehl V; Engert A
Cytokines Mol Ther; 1996 Sep; 2(3):139-46. PubMed ID: 9384698
[TBL] [Abstract][Full Text] [Related]
33. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
34. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain.
Kondo T; FitzGerald D; Chaudhary VK; Adhya S; Pastan I
J Biol Chem; 1988 Jul; 263(19):9470-5. PubMed ID: 3132465
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic activities of a fusion protein comprised of TGF alpha and Pseudomonas exotoxin.
Siegall CB; Xu YH; Chaudhary VK; Adhya S; Fitzgerald D; Pastan I
FASEB J; 1989 Dec; 3(14):2647-52. PubMed ID: 2556314
[TBL] [Abstract][Full Text] [Related]
36. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
[TBL] [Abstract][Full Text] [Related]
37. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Barth S; Huhn M; Wels W; Diehl V; Engert A
Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.
Wels W; Harwerth IM; Mueller M; Groner B; Hynes NE
Cancer Res; 1992 Nov; 52(22):6310-7. PubMed ID: 1358432
[TBL] [Abstract][Full Text] [Related]
39. Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines.
Amoozadeh S; Hemmati M; Farajollahi MM; Akbari N; Tarighi P
Cancer Invest; 2019; 37(10):546-557. PubMed ID: 31597492
[TBL] [Abstract][Full Text] [Related]
40. Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity.
Mixan B; Cohen BD; Bacus SS; Fell HP; Siegall CB
Oncogene; 1998 Mar; 16(9):1209-15. PubMed ID: 9528863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
